Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Can the upcoming J.P. Morgan Healthcare Conference next week trigger a flurry of biotech M&A deal making activity. Read more ...

Monte Rosa Therapeutics (GLUE) outlined anticipated 2025 milestones ahead of its participation in the 43rd Annual J.P. Morgan ...

Here is a list of healthcare conferences and links to registration.  Special thanks to Peter Grant and Global Healthcare LLC ...

John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will present at the 43rd Annual ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events ...

More than 8,000 healthcare professionals will descend on San Francisco starting Monday for the 43rd annual J.P. Morgan ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.